Last chance for new entrants to get in cheap. Knudson told us on 11/14 that a press release announcing 18-month data would happen AFTER said info was sent to the FDA. Knudson also expected the FDA to announce an advisory committee date BEFORE the end of the year. That could happen any day now; a long shot, but it has happened before, is that the FDA says a panel meeting is not necessary, as the new info clears up previous questions. The FDA works closely with their Australian counterpart and is well aware of how Enteromedics gained approval there.
It is common for next-day profit taking followed by another strong move up. Just a rumor of a partnership or buyout could double the stock price. Also, Euro news is due on whether additional CE marks are conferred for diabetes and hypertension.